The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
 
Julia Foldi
No Relationships to Disclose
 
Sarah Schellhorn Mougalian
Stock and Other Ownership Interests - Coronado Biosciences; Gilead Sciences; Roche
Consulting or Advisory Role - Eisai
Research Funding - Genentech; Pfizer
 
Andrea Silber
No Relationships to Disclose
 
Donald R. Lannin
No Relationships to Disclose
 
Brigid K. Killelea
No Relationships to Disclose
 
Anees B. Chagpar
No Relationships to Disclose
 
Nina Ruth Horowitz
No Relationships to Disclose
 
Courtney Frederick
No Relationships to Disclose
 
Lawrence Rispoli
No Relationships to Disclose
 
Maysa M. Abu-Khalaf
Research Funding - Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Kert D. Sabbath
Stock and Other Ownership Interests - Celgene; Johnson & Johnson
 
Tara Beth Sanft
No Relationships to Disclose
 
Neal A. Fischbach
No Relationships to Disclose
 
Debra S. Brandt
No Relationships to Disclose
 
Erin Wysong Hofstatter
No Relationships to Disclose
 
Michael DiGiovanna
No Relationships to Disclose
 
Lajos Pusztai
Honoraria - BioTheranostics; celgene; Merck; Pfizer
Consulting or Advisory Role - Celgene; Clovis Oncology
Research Funding - Foundation Medicine; Genentech; Merck; Seagen